Drug Approval | October 20, 2023
USFDA approves Pfizer’s Velsipity for adults with Ulcerative Colitis
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
Commenced operations in flood-affected Himachal Pradesh
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Subscribe To Our Newsletter & Stay Updated
